

Updated: 09/25/2025

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE & REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>SMOKING CESSATION</u>	A211901 NCT05008848	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>MULTICANCER EARLY DETECTION</u>	Alliance A212102 NCT05334069	Blinded Reference Set for Multicancer Early Detection Blood Tests	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>BREAST GASTRIC/ABDOMINAL THORACIC</u>	iCaRe ²	Integrated Cancer Repository for Cancer Research	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>LUNG ES-SCLC</u>	NRG-LU007 NCT04402788	Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>Breast Triple Negative</u>	Alliance A012103 NCT05812807	Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>Breast HR+ HER2-</u>	SWOG S2206 NCT0605837	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>Breast HR+ HER2-</u>	Alliance A012303 NCT06671912	Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (LoTam)	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PROSTATE</u>	NRG-GU010 NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PROSTATE</u>	NRG-GU013 NCT05946213	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org

<u>SKIN</u>	ECOG EA6174 NCT03712605	Pembrolizumab compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PANCREAS</u>	EA2192 NCT04858334	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>NSCLC</u>	ARTEMIDE Lung-02 NCT06692738	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>NSCLC</u>	TROPION- Lung12 NCT06564844	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>LEUKEMIA</u>	ReVenG NCT04895436	Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>SOLID TUMORS WITH BRAF ALTERATIONS</u>	FORE8394 MCT02428712	A phase 2 trial to assess the efficacy and safety of plixorafenib, an inhibitor of BRAF class I and II alterations, in patients with BRAF alterations	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>Breast, Colorectal, Melanoma, non-Hodgkin Lymphoma, NSCLC</u>	Wake Forest, Alliance WF2304- A172401 NCT06418204	Assessing Benefits and Harms of Cannabis/ Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org